Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant chemotherapy versus observation or mitotane after resection of localized adrenocortical carcinoma
2018-000580-90Phase 3Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, etoposide and mitotane in adrenal cancer (ACC) (2 arms), sponsored by ASST Spedali Civili di Brescia. Primary endpoints: Recurrence-free survival and Progression-free survival. Started Nov 2020; status: completed.
02
Drugs
cisplatinetoposidemitotane
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2018-000580-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000580-90.